Comparing Pyronaridine-Artesunate and Chloroquine for Malaria Treatment
Author Information
Author(s): Poravuth Yi, Socheat Duong, Rueangweerayut Ronnatrai, Uthaisin Chirapong, Pyae Phyo Aung, Valecha Neena, Rao B. H. Krishnamoorthy, Tjitra Emiliana, Purnama Asep, Borghini-Fuhrer Isabelle, Duparc Stephan, Shin Chang-Sik, Fleckenstein Lawrence
Primary Institution: National Malaria Center, Phnom Penh, Cambodia
Hypothesis
Is pyronaridine-artesunate non-inferior to chloroquine in treating uncomplicated P. vivax malaria?
Conclusion
Pyronaridine-artesunate is at least as effective as chloroquine for treating acute uncomplicated P. vivax malaria.
Supporting Evidence
- The Day-14 cure rate was 99.5% for pyronaridine-artesunate and 100% for chloroquine.
- Parasite clearance time was shorter with pyronaridine-artesunate (median 23.0 h) compared to chloroquine (32.0 h).
- Adverse events occurred in 40.4% of patients receiving pyronaridine-artesunate.
Takeaway
This study tested a new malaria treatment and found it works just as well as the old one, but it helps patients get better faster.
Methodology
A phase III randomized, double-blind, non-inferiority trial across five centers in Asia, comparing pyronaridine-artesunate and chloroquine in patients with confirmed P. vivax malaria.
Potential Biases
Potential bias due to exclusion of patients with mixed infections and reliance on microscopy for diagnosis.
Limitations
The study population was restricted and may not reflect the general population of malaria patients.
Participant Demographics
All participants were Asian/Oriental, mostly male (73.7%), with a mean age of 26.7 years.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95%CI 97.5, 100
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website